Neurocognitive function of children treated for high-risk B-acute lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus high-dose methotrexate (HDMTX): A report from the Children’s Oncology Group (COG).
Naomi Winick(The University of Texas Southwestern Medical Center), Robert B. Noll(University of Pittsburgh), Eric Larsen(University of Massachusetts Chan Medical School), Stephen P. Hunger(Children's Hospital of Philadelphia), Elizabeth A. Raetz(NYU Langone Health), John A. Kairalla(BC Children's Hospital), Mignon L. Loh(Seattle Children's Hospital), Leanne Embry(The University of Texas at San Antonio Health Science Center), Kristina K. Hardy(Children's National), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Daniel Armstrong(The University of Texas at San Antonio Health Science Center)
Cited by 0
Related Papers
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k